http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 02 Jun 2026 03:30:15 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Management+Changes/FundaMental+Pharma+names+Dr.+Hans+Eriksson+as+chief+medical+officer/26586072.html <p>FundaMental Pharma GmbH appointed Dr. Hans Eriksson as chief medical officer to advance development of its treatment-resistant depression candidate FMP374, the German biopharmaceutical company announced.</p> <p>Dr. Eriksson brings more than 25 years of clinical development experience across pharmaceutical and biotechnology companies, including positions at AstraZeneca, Lundbeck, Compass Pathways and HMNC Brain Health. He has contributed to eight late-phase clinical development programs in depression, three of which resulted in regulatory approvals for major depressive disorder.</p> <p>Most recently, Dr. Eriksson served as chief medical officer at HMNC Brain Health, where he led clinical development of Ketabon, an oral prolonged-release formulation of ketamine for major http://www.streetinsider.com/Management+Changes/FundaMental+Pharma+names+Dr.+Hans+Eriksson+as+chief+medical+officer/26586072.html Tue, 02 Jun 2026 03:30:15 -0400 A.21849991 CMPS O.20331252 O.47928049 http://www.streetinsider.com/Management+Changes/FundaMental+Pharma+names+Dr.+Hans+Eriksson+as+chief+medical+officer/26586072.html <p>FundaMental Pharma GmbH appointed Dr. Hans Eriksson as chief medical officer to advance development of its treatment-resistant depression candidate FMP374, the German biopharmaceutical company announced.</p> <p>Dr. Eriksson brings more than 25 years of clinical development experience across pharmaceutical and biotechnology companies, including positions at AstraZeneca, Lundbeck, Compass Pathways and HMNC Brain Health. He has contributed to eight late-phase clinical development programs in depression, three of which resulted in regulatory approvals for major depressive disorder.</p> <p>Most recently, Dr. Eriksson served as chief medical officer at HMNC Brain Health, where he led clinical development of Ketabon, an oral prolonged-release formulation of ketamine for major http://www.streetinsider.com/Management+Changes/FundaMental+Pharma+names+Dr.+Hans+Eriksson+as+chief+medical+officer/26586072.html Tue, 02 Jun 2026 03:30:15 -0400 A.21849991 CMPS O.20331252 O.47928049 http://www.streetinsider.com/Management+Changes/FundaMental+Pharma+names+Dr.+Hans+Eriksson+as+chief+medical+officer/26586072.html <p>FundaMental Pharma GmbH appointed Dr. Hans Eriksson as chief medical officer to advance development of its treatment-resistant depression candidate FMP374, the German biopharmaceutical company announced.</p> <p>Dr. Eriksson brings more than 25 years of clinical development experience across pharmaceutical and biotechnology companies, including positions at AstraZeneca, Lundbeck, Compass Pathways and HMNC Brain Health. He has contributed to eight late-phase clinical development programs in depression, three of which resulted in regulatory approvals for major depressive disorder.</p> <p>Most recently, Dr. Eriksson served as chief medical officer at HMNC Brain Health, where he led clinical development of Ketabon, an oral prolonged-release formulation of ketamine for major http://www.streetinsider.com/Management+Changes/FundaMental+Pharma+names+Dr.+Hans+Eriksson+as+chief+medical+officer/26586072.html Tue, 02 Jun 2026 03:30:15 -0400 A.21849991 CMPS O.20331252 O.47928049 http://www.streetinsider.com/Management+Changes/FundaMental+Pharma+names+Dr.+Hans+Eriksson+as+chief+medical+officer/26586072.html <p>FundaMental Pharma GmbH appointed Dr. Hans Eriksson as chief medical officer to advance development of its treatment-resistant depression candidate FMP374, the German biopharmaceutical company announced.</p> <p>Dr. Eriksson brings more than 25 years of clinical development experience across pharmaceutical and biotechnology companies, including positions at AstraZeneca, Lundbeck, Compass Pathways and HMNC Brain Health. He has contributed to eight late-phase clinical development programs in depression, three of which resulted in regulatory approvals for major depressive disorder.</p> <p>Most recently, Dr. Eriksson served as chief medical officer at HMNC Brain Health, where he led clinical development of Ketabon, an oral prolonged-release formulation of ketamine for major http://www.streetinsider.com/Management+Changes/FundaMental+Pharma+names+Dr.+Hans+Eriksson+as+chief+medical+officer/26586072.html Tue, 02 Jun 2026 03:30:15 -0400 A.21849991 CMPS O.20331252 O.47928049 http://www.streetinsider.com/Press+Releases/FundaMental+Pharma+appoints+depression+drug+developer+Dr.+Hans+Eriksson+as+Chief+Medical+Officer+to+advance+its+lead+treatment-resistant+depression+candidate/26586068.html <ul type="disc"><li><em>Exceptional track record across multiple clinical development programs for depression, three of which have resulted in regulatory approvals</em></li><li style="text-align:justify;"><em>Appointment strengthens confidence in clinical readiness and execution as the Company progresses toward first-in-human development </em></li></ul> <p align="justify">HEIDELBERG, Germany, June 02, 2026 (GLOBE NEWSWIRE) -- FundaMental Pharma GmbH (or “the Company”), a preclinical-stage biopharmaceutical company focused on developing innovative, dual-acting N-methyl-D-aspartate receptor (NMDAR) modulators aimed at delivering rapid and sustained relief for patients with treatment-resistant depression (TRD), today announces the appointment of Dr. Hans Eriksson as Chief Medical Officer.</p> <p align="justify">Dr. Eriksson brings more than 25 years http://www.streetinsider.com/Press+Releases/FundaMental+Pharma+appoints+depression+drug+developer+Dr.+Hans+Eriksson+as+Chief+Medical+Officer+to+advance+its+lead+treatment-resistant+depression+candidate/26586068.html Tue, 02 Jun 2026 03:30:00 -0400 A.21849991 CMPS O.20331252 O.47928049 http://www.streetinsider.com/Press+Releases/FundaMental+Pharma+appoints+depression+drug+developer+Dr.+Hans+Eriksson+as+Chief+Medical+Officer+to+advance+its+lead+treatment-resistant+depression+candidate/26586068.html <ul type="disc"><li><em>Exceptional track record across multiple clinical development programs for depression, three of which have resulted in regulatory approvals</em></li><li style="text-align:justify;"><em>Appointment strengthens confidence in clinical readiness and execution as the Company progresses toward first-in-human development </em></li></ul> <p align="justify">HEIDELBERG, Germany, June 02, 2026 (GLOBE NEWSWIRE) -- FundaMental Pharma GmbH (or “the Company”), a preclinical-stage biopharmaceutical company focused on developing innovative, dual-acting N-methyl-D-aspartate receptor (NMDAR) modulators aimed at delivering rapid and sustained relief for patients with treatment-resistant depression (TRD), today announces the appointment of Dr. Hans Eriksson as Chief Medical Officer.</p> <p align="justify">Dr. Eriksson brings more than 25 years http://www.streetinsider.com/Press+Releases/FundaMental+Pharma+appoints+depression+drug+developer+Dr.+Hans+Eriksson+as+Chief+Medical+Officer+to+advance+its+lead+treatment-resistant+depression+candidate/26586068.html Tue, 02 Jun 2026 03:30:00 -0400 A.21849991 CMPS O.20331252 O.47928049 http://www.streetinsider.com/Press+Releases/FundaMental+Pharma+appoints+depression+drug+developer+Dr.+Hans+Eriksson+as+Chief+Medical+Officer+to+advance+its+lead+treatment-resistant+depression+candidate/26586068.html <ul type="disc"><li><em>Exceptional track record across multiple clinical development programs for depression, three of which have resulted in regulatory approvals</em></li><li style="text-align:justify;"><em>Appointment strengthens confidence in clinical readiness and execution as the Company progresses toward first-in-human development </em></li></ul> <p align="justify">HEIDELBERG, Germany, June 02, 2026 (GLOBE NEWSWIRE) -- FundaMental Pharma GmbH (or “the Company”), a preclinical-stage biopharmaceutical company focused on developing innovative, dual-acting N-methyl-D-aspartate receptor (NMDAR) modulators aimed at delivering rapid and sustained relief for patients with treatment-resistant depression (TRD), today announces the appointment of Dr. Hans Eriksson as Chief Medical Officer.</p> <p align="justify">Dr. Eriksson brings more than 25 years http://www.streetinsider.com/Press+Releases/FundaMental+Pharma+appoints+depression+drug+developer+Dr.+Hans+Eriksson+as+Chief+Medical+Officer+to+advance+its+lead+treatment-resistant+depression+candidate/26586068.html Tue, 02 Jun 2026 03:30:00 -0400 A.21849991 CMPS O.20331252 O.47928049 http://www.streetinsider.com/Press+Releases/FundaMental+Pharma+appoints+depression+drug+developer+Dr.+Hans+Eriksson+as+Chief+Medical+Officer+to+advance+its+lead+treatment-resistant+depression+candidate/26586068.html <ul type="disc"><li><em>Exceptional track record across multiple clinical development programs for depression, three of which have resulted in regulatory approvals</em></li><li style="text-align:justify;"><em>Appointment strengthens confidence in clinical readiness and execution as the Company progresses toward first-in-human development </em></li></ul> <p align="justify">HEIDELBERG, Germany, June 02, 2026 (GLOBE NEWSWIRE) -- FundaMental Pharma GmbH (or “the Company”), a preclinical-stage biopharmaceutical company focused on developing innovative, dual-acting N-methyl-D-aspartate receptor (NMDAR) modulators aimed at delivering rapid and sustained relief for patients with treatment-resistant depression (TRD), today announces the appointment of Dr. Hans Eriksson as Chief Medical Officer.</p> <p align="justify">Dr. Eriksson brings more than 25 years http://www.streetinsider.com/Press+Releases/FundaMental+Pharma+appoints+depression+drug+developer+Dr.+Hans+Eriksson+as+Chief+Medical+Officer+to+advance+its+lead+treatment-resistant+depression+candidate/26586068.html Tue, 02 Jun 2026 03:30:00 -0400 A.21849991 CMPS O.20331252 O.47928049 http://www.streetinsider.com/Globe+Newswire/FundaMental+Pharma+appoints+depression+drug+developer+Dr.+Hans+Eriksson+as+Chief+Medical+Officer+to+advance+its+lead+treatment-resistant+depression+candidate/26586068.html <ul type="disc"><li><em>Exceptional track record across multiple clinical development programs for depression, three of which have resulted in regulatory approvals</em></li><li style="text-align:justify;"><em>Appointment strengthens confidence in clinical readiness and execution as the Company progresses toward first-in-human development </em></li></ul> <p align="justify">HEIDELBERG, Germany, June 02, 2026 (GLOBE NEWSWIRE) -- FundaMental Pharma GmbH (or “the Company”), a preclinical-stage biopharmaceutical company focused on developing innovative, dual-acting N-methyl-D-aspartate receptor (NMDAR) modulators aimed at delivering rapid and sustained relief for patients with treatment-resistant depression (TRD), today announces the appointment of Dr. Hans Eriksson as Chief Medical Officer.</p> <p align="justify">Dr. Eriksson brings more than 25 years http://www.streetinsider.com/Globe+Newswire/FundaMental+Pharma+appoints+depression+drug+developer+Dr.+Hans+Eriksson+as+Chief+Medical+Officer+to+advance+its+lead+treatment-resistant+depression+candidate/26586068.html Tue, 02 Jun 2026 03:30:00 -0400 A.21849991 CMPS O.20331252 O.47928049 http://www.streetinsider.com/Globe+Newswire/FundaMental+Pharma+appoints+depression+drug+developer+Dr.+Hans+Eriksson+as+Chief+Medical+Officer+to+advance+its+lead+treatment-resistant+depression+candidate/26586068.html <ul type="disc"><li><em>Exceptional track record across multiple clinical development programs for depression, three of which have resulted in regulatory approvals</em></li><li style="text-align:justify;"><em>Appointment strengthens confidence in clinical readiness and execution as the Company progresses toward first-in-human development </em></li></ul> <p align="justify">HEIDELBERG, Germany, June 02, 2026 (GLOBE NEWSWIRE) -- FundaMental Pharma GmbH (or “the Company”), a preclinical-stage biopharmaceutical company focused on developing innovative, dual-acting N-methyl-D-aspartate receptor (NMDAR) modulators aimed at delivering rapid and sustained relief for patients with treatment-resistant depression (TRD), today announces the appointment of Dr. Hans Eriksson as Chief Medical Officer.</p> <p align="justify">Dr. Eriksson brings more than 25 years http://www.streetinsider.com/Globe+Newswire/FundaMental+Pharma+appoints+depression+drug+developer+Dr.+Hans+Eriksson+as+Chief+Medical+Officer+to+advance+its+lead+treatment-resistant+depression+candidate/26586068.html Tue, 02 Jun 2026 03:30:00 -0400 A.21849991 CMPS O.20331252 O.47928049 http://www.streetinsider.com/Globe+Newswire/FundaMental+Pharma+appoints+depression+drug+developer+Dr.+Hans+Eriksson+as+Chief+Medical+Officer+to+advance+its+lead+treatment-resistant+depression+candidate/26586068.html <ul type="disc"><li><em>Exceptional track record across multiple clinical development programs for depression, three of which have resulted in regulatory approvals</em></li><li style="text-align:justify;"><em>Appointment strengthens confidence in clinical readiness and execution as the Company progresses toward first-in-human development </em></li></ul> <p align="justify">HEIDELBERG, Germany, June 02, 2026 (GLOBE NEWSWIRE) -- FundaMental Pharma GmbH (or “the Company”), a preclinical-stage biopharmaceutical company focused on developing innovative, dual-acting N-methyl-D-aspartate receptor (NMDAR) modulators aimed at delivering rapid and sustained relief for patients with treatment-resistant depression (TRD), today announces the appointment of Dr. Hans Eriksson as Chief Medical Officer.</p> <p align="justify">Dr. Eriksson brings more than 25 years http://www.streetinsider.com/Globe+Newswire/FundaMental+Pharma+appoints+depression+drug+developer+Dr.+Hans+Eriksson+as+Chief+Medical+Officer+to+advance+its+lead+treatment-resistant+depression+candidate/26586068.html Tue, 02 Jun 2026 03:30:00 -0400 A.21849991 CMPS O.20331252 O.47928049 http://www.streetinsider.com/Globe+Newswire/FundaMental+Pharma+appoints+depression+drug+developer+Dr.+Hans+Eriksson+as+Chief+Medical+Officer+to+advance+its+lead+treatment-resistant+depression+candidate/26586068.html <ul type="disc"><li><em>Exceptional track record across multiple clinical development programs for depression, three of which have resulted in regulatory approvals</em></li><li style="text-align:justify;"><em>Appointment strengthens confidence in clinical readiness and execution as the Company progresses toward first-in-human development </em></li></ul> <p align="justify">HEIDELBERG, Germany, June 02, 2026 (GLOBE NEWSWIRE) -- FundaMental Pharma GmbH (or “the Company”), a preclinical-stage biopharmaceutical company focused on developing innovative, dual-acting N-methyl-D-aspartate receptor (NMDAR) modulators aimed at delivering rapid and sustained relief for patients with treatment-resistant depression (TRD), today announces the appointment of Dr. Hans Eriksson as Chief Medical Officer.</p> <p align="justify">Dr. Eriksson brings more than 25 years http://www.streetinsider.com/Globe+Newswire/FundaMental+Pharma+appoints+depression+drug+developer+Dr.+Hans+Eriksson+as+Chief+Medical+Officer+to+advance+its+lead+treatment-resistant+depression+candidate/26586068.html Tue, 02 Jun 2026 03:30:00 -0400 A.21849991 CMPS O.20331252 O.47928049 http://www.streetinsider.com/Analyst+Comments/TD+Cowen+on+Compass+Pathways+%28CMPS%29+Amid+%2B10%25+Gain+Today%3A+%27e+continue+to+model+%27360+approval+in+1H27%27/26582398.html <p>TD Cowen analyst Ritu Baral reiterated a Buy rating and $29.00 price target on Compass Pathways (NASDAQ: CMPS).</p><p>The analyst comments "At/before ASCP, academic/commercial interventional psych KOLs highlight strong early demand for '360 in TRD, w/ use in academic centers likely to be constrained by site capacity. Both will rigorously screen pts at launch to prioritize safety. The FDA session highlighted engagement but also capacity constraints (incl around Adcomms, new guidance docs); we continue to model '360 approval in 1H27. At ASCP 2026 (Miami), CMPS presented Ph3 COMP360 TRD data from their PBO-controlled '005 and repeat-dose '006 studies. An FDA plenary http://www.streetinsider.com/Analyst+Comments/TD+Cowen+on+Compass+Pathways+%28CMPS%29+Amid+%2B10%25+Gain+Today%3A+%27e+continue+to+model+%27360+approval+in+1H27%27/26582398.html Mon, 01 Jun 2026 13:43:42 -0400 CMPS http://www.streetinsider.com/Hot+Comments/TD+Cowen+on+Compass+Pathways+%28CMPS%29+Amid+%2B10%25+Gain+Today%3A+%27e+continue+to+model+%27360+approval+in+1H27%27/26582398.html <p>TD Cowen analyst Ritu Baral reiterated a Buy rating and $29.00 price target on Compass Pathways (NASDAQ: CMPS).</p><p>The analyst comments "At/before ASCP, academic/commercial interventional psych KOLs highlight strong early demand for '360 in TRD, w/ use in academic centers likely to be constrained by site capacity. Both will rigorously screen pts at launch to prioritize safety. The FDA session highlighted engagement but also capacity constraints (incl around Adcomms, new guidance docs); we continue to model '360 approval in 1H27. At ASCP 2026 (Miami), CMPS presented Ph3 COMP360 TRD data from their PBO-controlled '005 and repeat-dose '006 studies. An FDA plenary http://www.streetinsider.com/Hot+Comments/TD+Cowen+on+Compass+Pathways+%28CMPS%29+Amid+%2B10%25+Gain+Today%3A+%27e+continue+to+model+%27360+approval+in+1H27%27/26582398.html Mon, 01 Jun 2026 13:43:42 -0400 CMPS http://www.streetinsider.com/SEC+Filings/Form++4++++++++++COMPASS+Pathways+plc++++++For%3A+May+27++Filed+by%3A+Karydas+Daphne/26576752.html si-local-file:///var/storage/secattach/20260529/26576752.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++COMPASS+Pathways+plc++++++For%3A+May+27++Filed+by%3A+Karydas+Daphne/26576752.html Fri, 29 May 2026 17:32:00 -0400 CMPS O.47928049 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++COMPASS+Pathways+plc++++++For%3A+May+27++Filed+by%3A+Karydas+Daphne/26576752.html si-local-file:///var/storage/secattach/20260529/26576752.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++COMPASS+Pathways+plc++++++For%3A+May+27++Filed+by%3A+Karydas+Daphne/26576752.html Fri, 29 May 2026 17:32:00 -0400 CMPS O.47928049 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++COMPASS+Pathways+plc++++++For%3A+May+27++Filed+by%3A+SANTINI+GINO/26576694.html si-local-file:///var/storage/secattach/20260529/26576694.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++COMPASS+Pathways+plc++++++For%3A+May+27++Filed+by%3A+SANTINI+GINO/26576694.html Fri, 29 May 2026 17:27:00 -0400 CMPS O.47928049 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++COMPASS+Pathways+plc++++++For%3A+May+27++Filed+by%3A+SANTINI+GINO/26576694.html si-local-file:///var/storage/secattach/20260529/26576694.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++COMPASS+Pathways+plc++++++For%3A+May+27++Filed+by%3A+SANTINI+GINO/26576694.html Fri, 29 May 2026 17:27:00 -0400 CMPS O.47928049 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++COMPASS+Pathways+plc++++++For%3A+May+27++Filed+by%3A+Gover+Justin+D./26576569.html si-local-file:///var/storage/secattach/20260529/26576569.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++COMPASS+Pathways+plc++++++For%3A+May+27++Filed+by%3A+Gover+Justin+D./26576569.html Fri, 29 May 2026 17:18:00 -0400 CMPS O.47928049 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++COMPASS+Pathways+plc++++++For%3A+May+27++Filed+by%3A+Gover+Justin+D./26576569.html si-local-file:///var/storage/secattach/20260529/26576569.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++COMPASS+Pathways+plc++++++For%3A+May+27++Filed+by%3A+Gover+Justin+D./26576569.html Fri, 29 May 2026 17:18:00 -0400 CMPS O.47928049 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++COMPASS+Pathways+plc++++++For%3A+May+27++Filed+by%3A+JONAS+JEFFREY+M/26576553.html si-local-file:///var/storage/secattach/20260529/26576553.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++COMPASS+Pathways+plc++++++For%3A+May+27++Filed+by%3A+JONAS+JEFFREY+M/26576553.html Fri, 29 May 2026 17:16:00 -0400 CMPS O.47928049 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++COMPASS+Pathways+plc++++++For%3A+May+27++Filed+by%3A+JONAS+JEFFREY+M/26576553.html si-local-file:///var/storage/secattach/20260529/26576553.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++COMPASS+Pathways+plc++++++For%3A+May+27++Filed+by%3A+JONAS+JEFFREY+M/26576553.html Fri, 29 May 2026 17:16:00 -0400 CMPS O.47928049 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++COMPASS+Pathways+plc++++++For%3A+May+27++Filed+by%3A+Riley+Wayne+Joseph/26576522.html si-local-file:///var/storage/secattach/20260529/26576522.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++COMPASS+Pathways+plc++++++For%3A+May+27++Filed+by%3A+Riley+Wayne+Joseph/26576522.html Fri, 29 May 2026 17:14:00 -0400 CMPS O.47928049 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++COMPASS+Pathways+plc++++++For%3A+May+27++Filed+by%3A+Riley+Wayne+Joseph/26576522.html si-local-file:///var/storage/secattach/20260529/26576522.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++COMPASS+Pathways+plc++++++For%3A+May+27++Filed+by%3A+Riley+Wayne+Joseph/26576522.html Fri, 29 May 2026 17:14:00 -0400 CMPS O.47928049 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++COMPASS+Pathways+plc++++++For%3A+May+27++Filed+by%3A+Norton+David+Y/26576500.html si-local-file:///var/storage/secattach/20260529/26576500.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++COMPASS+Pathways+plc++++++For%3A+May+27++Filed+by%3A+Norton+David+Y/26576500.html Fri, 29 May 2026 17:12:00 -0400 CMPS O.47928049